Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations

References

• National Cancer Institute (NCI). General information about adult aculte myeloid leukemia. Adult Acute Myeloid Leukemia Treatment (PDQ®)- Patient Version. 2016. Available at: http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
   Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Acute Myeloid Leukemia (AML). 2016. http://seer.cancer.gov/statfacts/html/amyl.html.
   Google Scholar
• American Cancer Society. What are the key statistics about acute myeloid leukemia? 2017. Available at: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html
   Google Scholar
• Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107:2099-107
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Typical treatment of most types of acute myeloid leukemia. 2017. Available at: https://www.cancer.org/cancer/acute-myeloid-leukemia/treating/typical-treatment-of-aml.html
   Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322-33
   PubMed Web of Science ®Google Scholar
• Rowley JD, Alimena G, Garson OM, et al. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood 1982;59:1013-22
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN guidelines: acute myeloid leukemia. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
   Google Scholar
• Meyers J, Yu Y, Davis K. Patient survival, health care utilization, and costs in Medicare patients with acute myeloid leukemia compared with matched controls. ISPOR 17th Annual International Meeting; Washington, DC. 2014
   Google Scholar
• Mahmoud D, Skikne B, Kucmin-Bemelmans I, et al. Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease. Blood 2012;120:3614
   Web of Science ®Google Scholar
• Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT, et al. Economic burden associated with acute myeloid leukemia treatment. Expert Rev Hematol 2016;9:79-89
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162:1597-603
   PubMed Web of Science ®Google Scholar
• Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy 2013;11:275-86
   PubMedGoogle Scholar
• Thomas X, Le Jeune C. Treatment of elderly patients with acute myeloid leukemia. Curr Treat Options Oncol 2017;18:2
   PubMed Web of Science ®Google Scholar
• Brandwein JM, Geddes M, Kassis J, et al. Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus. Am J Blood Res 2013;3:141-64
   PubMedGoogle Scholar
• Rathnasabapathy R, Lancet JE. Management of acute myelogenous leukemia in the elderly. Cancer Control 2003;10:469-77
   PubMedGoogle Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-87
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9
   PubMed Web of Science ®Google Scholar
• Preussler JM, Meyer CL, Mau LW, et al. Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2017;23:1021-8
   PubMed Web of Science ®Google Scholar
• Irish W, Ryan M, Gache L, et al. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Curr Med Res Opin 2017;33:519-27
   PubMed Web of Science ®Google Scholar
• Jeffrey D, Miller M, Truven Health Analytics. Truven Health White Paper: Using MarketScan data for economic modeling studies. Truven Health Analytics; 2015
   Google Scholar
• National Cancer Institute (NCI). SEER-Medicare linked database. 2016. Available at: https://healthcaredelivery.cancer.gov/seermedicare
   Google Scholar
• Craig BM, Rollison DE, List AF, et al. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev 2012;21:474-81
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics- US Department of Labor. Consumer price index. 2016. Available at: https://www.bls.gov/cpi/
   Google Scholar
• Ortman J, Velkoff V, Hogan H. An aging nation: the older population in the United States, population estimates and projections [online report]. United States Census Bureau; 2012. Available at: https://www.census.gov/prod/2014pubs/p25-1140.pdf
   Google Scholar
• Alibhai SMH, Leach M, Minden MD, et al. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 2009;115:2903-11
   PubMed Web of Science ®Google Scholar
• Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leukemia Res Reports 2016;6:1-7
   PubMedGoogle Scholar
• Redaelli A, Botteman MF, Stephens JM, et al. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev 2004;30:237-47
   PubMed Web of Science ®Google Scholar
• Moller T, Nielsen OJ, Welinder P, et al. Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. Eur J Haematol 2010;84:316-22
   PubMed Web of Science ®Google Scholar
• Walter RB, Lee SJ, Gardner KM, et al. Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. Haematologica 2011;96:914-17
   PubMed Web of Science ®Google Scholar
• Vaughn JE, Othus M, Powell MA, et al. Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: a nonrandomized clinical comparative analysis. JAMA Oncol 2015;1:1120-7
   PubMed Web of Science ®Google Scholar
• Stein EM, Yang M, Guerin A, et al. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. Value in Health 2017;20:A223-A223
   Google Scholar
• El-Jawahri AR, Traeger LN, Kuzmuk K, Eusebio JR, Vandusen HB, Shin JA, et al. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer 2015;121:951-9
   PubMed Web of Science ®Google Scholar
• El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. Jama 2016;316:2094-103
   PubMed Web of Science ®Google Scholar
• Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood 2016;127:71-8
   PubMed Web of Science ®Google Scholar
• Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013;10:460-71
   PubMed Web of Science ®Google Scholar